Reed Stephens

Practice Areas

Reed is a nationally recognized legal authority in the life sciences industry, as well as the pharmaceutical fraud and abuse and corporate compliance spaces, and focuses his practice on fraud and abuse defense, corporate compliance, and risk management across the full spectrum of healthcare providers, managed care organizations, pharmaceutical manufacturers and medical device companies. He has extensive experience with the Anti-Kickback Statute and Stark Physician Self-Referral Law, and False Claims Act litigation.

Reed represents pharmaceutical and biotech manufacturers, wholesalers and individuals, healthcare systems, and non-healthcare-related companies in various global industries. This includes the defense industry, government contractors in the gaming industry, as well as the financial services and banking sectors. He has experience in matters involving state and federal government law enforcement and U.S. congressional investigations. He represents health systems and managed care organizations in federal False Claims Act litigation, and counsels pharmaceutical manufacturers on government drug pricing and voluntary disclosures in the areas of Medicaid Drug Rebate, Federal Supply Schedule/Department of Veterans Affairs, and the 340B program.

Furthermore, Reed advises his clients—including private equity sponsors—and provides employee training on risk management concerns involving mergers and acquisitions, post-merger integration compliance and disclosure of misconduct, public policy and legislative developments, supply chain disputes, and an array of regulatory compliance matters concerning product marketing and foreign anti-corruption statutes.

Previously, Reed was a Trial Attorney with the Civil Frauds Section within the U.S. Department of Justice Civil Division, where he led more than 60 federal False Claims Act investigations—the majority involving allegations of healthcare fraud perpetrated against various government agencies. Reed was lead counsel for the U.S. in the first successful government price reporting cases against the pharmaceutical industry, involving Medicare and Medicaid Average Wholesale Price reporting (US ex rel. Ven-A-Care v. et al.); Medicaid Drug Rebate price reporting (US ex rel. Foster v. Parke-Davis, US ex rel. Alcorn v. Schering-Plough); and the Prescription Drug Marketing Act fraud (US ex rel. Gerstein v. TAP Pharmaceuticals).